Skip to main content
DNA analysis using a multichannel pipette to load reaction mixtures into a 96-well plate for molecular assay validation and quality control

The Role of Reference Materials in Cell-Free DNA Testing

Cell-free DNA (cfDNA) testing has become central to modern liquid biopsy workflows, enabling molecular laboratories to detect clinically relevant genomic alterations from plasma samples. As liquid biopsy applications expand across therapy selection, treatment monitoring and molecular residual disease assessment, laboratories must demonstrate that assay performance remains accurate, reproducible and fit for purpose.

Unlike tissue testing, cfDNA assays often operate at the limits of detection. Circulating tumour DNA (ctDNA) may represent less than 1% of total cfDNA, making analytical sensitivity dependent on the entire workflow, from sample collection and extraction through sequencing, bioinformatics and long-term quality monitoring. Robust quality control strategies and well-characterised reference materials are therefore essential for assay validation, verification and ongoing performance monitoring. [1]

Why cfDNA testing is challenging

Liquid biopsy assays must identify a small number of tumour-derived molecules against a large background of wild-type DNA. Success depends on multiple factors working together, including:

  • Pre-analytical sample handling
  • DNA extraction and recovery
  • Library preparation efficiency
  • Sequencing quality
  • Bioinformatic error suppression
  • Ongoing quality monitoring

Even highly sensitive assays can be affected by variability introduced before sequencing begins. Performance is determined by the entire workflow, not a single analytical step.

The impact of pre-analytical variables

One of the largest sources of variation in cfDNA testing occurs during sample collection and processing. Factors such as blood collection tube selection, transport conditions, storage, haemolysis and time to plasma separation can significantly affect ctDNA recovery.

Delayed plasma separation can lead to white blood cell lysis and the release of genomic DNA, increasing background DNA levels and diluting tumour-derived signals. This can reduce the apparent tumour fraction and make low-frequency variants more difficult to detect. [3,4]

For assays operating near their analytical limits, effective pre-analytical control is often as important as sequencing performance itself.

Detecting variants below 1% VAF

Many liquid biopsy assays are designed to detect variants at variant allele frequencies (VAFs) below 1%. Demonstrating this level of sensitivity requires more than a single successful detection. Laboratories must show that low-frequency variants can be detected consistently and reproducibly under routine testing conditions. [1,2]

Analytical sensitivity is influenced by:

  • Variant allele frequency
  • Molecular input
  • Sequencing depth
  • Library preparation performance
  • Background error rate
  • Bioinformatic filtering and error suppression

Modern workflows often incorporate unique molecular identifiers (UMIs), consensus read generation and error-corrected bioinformatics to distinguish true variants from technical artefacts. Validation studies using characterised reference materials help establish parameters such as limit of detection (LoD), precision, reproducibility and detection probability at clinically relevant thresholds. [1,2]

Importantly, a negative or inconclusive liquid biopsy result is not always the result of assay failure. Low tumour fraction may limit the number of mutant molecules entering the workflow, reducing the likelihood of variant detection even when downstream analytical performance is optimal. [1]

Choosing the right reference material

Reference materials provide the evidence needed to support assay validation, establish analytical sensitivity, verify limit of detection claims, monitor assay drift and underpin ongoing quality assurance throughout the assay lifecycle.

However, different materials serve different purposes. Contrived controls provide highly characterised, scalable materials that support standardisation and routine monitoring. Patient-derived controls offer greater biological relevance and more closely reflect clinical sample behaviour during extraction and sequencing.

Many laboratories use a combination of both to balance consistency with real-world performance assessment.

A key consideration is commutability, the ability of a control material to behave like a clinical specimen throughout the testing workflow. A control may contain the correct variant at the correct concentration, but if it does not replicate cfDNA fragmentation, extraction characteristics or molecular complexity, it may not provide a realistic assessment of assay performance. [5,6]

Maintaining performance over time

Assay performance can change over time due to reagent lots, instrument maintenance, workflow modifications, software updates or environmental factors. Sensitivity claims should not be treated as fixed. Changes across the workflow can influence performance, making periodic re-verification an important part of assay lifecycle management. [1]

Key monitoring activities typically include:

  • Low-frequency variant recovery assessment
  • Positive and negative control monitoring
  • Background error rate evaluation
  • Reproducibility testing
  • Lot-to-lot comparison studies
  • Trend analysis of longitudinal QC data

These activities help identify analytical drift before patient reporting is affected and provide confidence that original validation claims remain supported over time.

The value of external quality assessment

External quality assessment (EQA) and proficiency testing provide an independent measure of laboratory performance. EQA programmes help laboratories verify that assay performance remains aligned with validation claims, accreditation requirements and industry expectations. [1]

Participation provides independent evidence that liquid biopsy workflows continue to perform as expected under routine testing conditions.

Building a robust cfDNA QC strategy

An effective cfDNA quality framework should evaluate the entire workflow, not just sequencing performance. Key components include:

  • Pre-analytical controls to monitor collection, handling and processing
  • Extraction controls to assess DNA recovery and quality
  • Analytical controls to verify sensitivity and specificity
  • Long-term monitoring to detect assay drift
  • External quality assessment to benchmark ongoing performance

By aligning reference material selection with validation, verification and monitoring objectives, laboratories can generate confidence in assay sensitivity, support regulatory and accreditation requirements, and maintain reliable clinical reporting throughout the assay lifecycle. [1,2]

References

  1. Lockwood CM et al. Recommendations for Cell-Free DNA Assay Validations: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists. Journal of Molecular Diagnostics. 2023.
  2. Clinical and Laboratory Standards Institute (CLSI). MM17: Validation and Verification of Multiplex Nucleic Acid Assays, 2nd Edition. Wayne, PA: CLSI; 2018.
  3. Peng H et al. The Impact of Preanalytical Variables on the Analysis of Cell-Free DNA from Blood and Urine Samples. Frontiers in Cell and Developmental Biology. 2024.
  4. van der Pol Y et al. The Effect of Preanalytical and Physiological Variables on Cell-Free DNA Fragmentation. Clinical Chemistry. 2022.
  5. Camara J et al. Recommendations for Assessing Commutability Part 1: General Experimental Design. Clinical Chemistry. 2018.
  6. Miller WG et al. Recommendations for Setting a Criterion for Assessing Commutability of Secondary Calibrator Certified Reference Materials. 2023.

Frequently asked questions

Why is cfDNA testing more challenging than tissue testing?

ctDNA often represents only a small fraction of total cfDNA, requiring reliable detection of very low-frequency variants against a much larger background of normal DNA.

What causes failed or inconclusive liquid biopsy results?

Common causes include low tumour fraction, insufficient molecular input or failure to meet predefined quality control thresholds.

What is commutability?

Commutability describes how closely a reference material behaves like a real clinical sample throughout extraction, library preparation, sequencing and variant analysis.

How is sensitivity below 1% VAF verified?

Typically through testing characterised low-frequency reference materials across multiple replicates to demonstrate consistent and reproducible detection at the claimed threshold.

Why is ongoing verification important?

Changes in reagents, instruments, software and workflows can affect analytical sensitivity over time, making periodic reassessment essential.

Strengthen your cfDNA quality strategy

Reliable cfDNA testing requires more than analytical sensitivity. It requires a quality framework that supports validation, verification and ongoing performance monitoring across the entire liquid biopsy workflow.